Lv1
59 积分 2021-07-21 加入
Non-invasive risk scores for prediction of type 2 diabetes (EPIC-InterAct): a validation of existing models
17小时前
已关闭
The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis
1天前
已完结
Implementing sustainable liver health in Europe: a second EASL–Lancet Commission
2天前
已完结
Efficacy and safety of ervogastat alone and in combination with clesacostat in patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis and F2–F3 fibrosis (MIRNA): results from a phase 2, randomised, double-blind, double-dummy study
2天前
已完结
Global burden of metabolic dysfunction-associated steatotic liver disease, 1990–2023, and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2023
2天前
已完结
Expert panel perspectives on improving the diagnosis and management of metabolic dysfunction-associated steatohepatitis in Denmark
4天前
已关闭
The use of pharmacotherapies in non-cirrhotic metabolic dysfunction-associated steatohepatitis: a UK expert consensus
4天前
已完结
Clinical trial design, biomarkers and end points in metabolic and alcohol-related liver disease
8天前
已完结
Implementing sustainable liver health in Europe: a second EASL–Lancet Commission
10天前
已完结
The use of pharmacotherapies in non-cirrhotic metabolic dysfunction-associated steatohepatitis: a UK expert consensus
11天前
已完结
皖公网安备34019202002308
